295 related articles for article (PubMed ID: 34425741)
1. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Chiloiro S; De Marinis L
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1744-1759. PubMed ID: 34425741
[TBL] [Abstract][Full Text] [Related]
2. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
3. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal.
Villa C; Vasiljevic A; Jaffrain-Rea ML; Ansorge O; Asioli S; Barresi V; Chinezu L; Gardiman MP; Lania A; Lapshina AM; Poliani L; Reiniger L; Righi A; Saeger W; Soukup J; Theodoropoulou M; Uccella S; Trouillas J; Roncaroli F
Virchows Arch; 2019 Dec; 475(6):687-692. PubMed ID: 31578606
[TBL] [Abstract][Full Text] [Related]
4. Update on the Genetics of Pituitary Tumors.
Barry S; Korbonits M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):433-452. PubMed ID: 32741481
[TBL] [Abstract][Full Text] [Related]
5. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
6. Pituitary adenoma…nomen omen?
Giustina A
Endocrine; 2021 Oct; 74(1):1-4. PubMed ID: 34114192
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
8. Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?
Martínez-López S; García-Martínez A; Torregrosa-Quesada ME; López-Muñoz B; Cámara R; Fajardo C; Lamas C; Picó A
J Endocrinol Invest; 2020 Jun; 43(6):859-863. PubMed ID: 31898311
[TBL] [Abstract][Full Text] [Related]
9. Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.
Whyte E; Nezu M; Chik C; Tateno T
Endocrinol Metab (Seoul); 2023 Dec; 38(6):631-654. PubMed ID: 37964483
[TBL] [Abstract][Full Text] [Related]
10. A review of multiomics platforms in pituitary adenoma pathogenesis.
Mouchtouris N; Smit RD; Piper K; Prashant G; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Mar; 27(3):77. PubMed ID: 35345309
[TBL] [Abstract][Full Text] [Related]
11. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
[TBL] [Abstract][Full Text] [Related]
12. Can the molecular typing of the specific adenohypophyseal hormone genes be useful in the management of pituitary neuroendocrine tumours?
Miralles Moragrega R; García-Martínez A; Picó A; Aranda I; Argente Villaplana CR
Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(6):395-397. PubMed ID: 30878680
[No Abstract] [Full Text] [Related]
13. From Benign to Malignant: The Arrival of Pituitary Neuroendocrine Tumors (PitNETs).
Meagher T
J Insur Med; 2023 Jul; 50(2):154-156. PubMed ID: 38358922
[TBL] [Abstract][Full Text] [Related]
14. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
15. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.
Keil MF; Stratakis CA
Expert Rev Neurother; 2008 Apr; 8(4):563-74. PubMed ID: 18416659
[TBL] [Abstract][Full Text] [Related]
16. [Recent Progress in Treatments of Pituitary Neuroendocrine Tumors(Pituitary Tumors)].
Nishioka H
No Shinkei Geka; 2024 May; 52(3):631-645. PubMed ID: 38783506
[TBL] [Abstract][Full Text] [Related]
17. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Vialon M; Desailloud R; Caron P
Ann Endocrinol (Paris); 2019 Sep; 80 Suppl 1():S19-S28. PubMed ID: 31606058
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors.
Asa SL
Endocr Pathol; 2021 Jun; 32(2):222-227. PubMed ID: 33866514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
